These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 15530836)

  • 41. Current approaches in ovarian cancer vaccines.
    Reinartz S; Wagner U
    Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical trials with tumor antigen genetically modified dendritic cells.
    Ribas A
    Semin Oncol; 2005 Dec; 32(6):556-62. PubMed ID: 16338421
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes.
    Grünebach F; Kayser K; Weck MM; Müller MR; Appel S; Brossart P
    Cancer Gene Ther; 2005 Sep; 12(9):749-56. PubMed ID: 15877082
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
    Shojaeian J; Jeddi-Tehrani M; Dokouhaki P; Mahmoudi AR; Ghods R; Bozorgmehr M; Nikoo S; Bayat AA; Akhondi MM; Ostadkarampour M; Rezania S; Zarnani AH
    J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cell biology: The ins and outs of exosomes.
    Couzin J
    Science; 2005 Jun; 308(5730):1862-3. PubMed ID: 15976285
    [No Abstract]   [Full Text] [Related]  

  • 46. Dendritic cell based immunotherapy--a promising therapeutic approach for endocrine malignancies.
    Sbiera S; Wortmann S; Fassnacht M
    Horm Metab Res; 2008 Feb; 40(2):89-98. PubMed ID: 18283626
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.
    Mason NJ; Coughlin CM; Overley B; Cohen JN; Mitchell EL; Colligon TA; Clifford CA; Zurbriggen A; Sorenmo KU; Vonderheide RH
    Gene Ther; 2008 Jul; 15(13):955-65. PubMed ID: 18337841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dendritic cells and antigen trapping technology--a revolution in vaccine/immunotherapy strategy.
    Pal C; Ganguly D; Paul K; Pal S
    Indian J Exp Biol; 2007 Jun; 45(6):491-504. PubMed ID: 17585683
    [TBL] [Abstract][Full Text] [Related]  

  • 50. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
    Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
    J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo.
    Hanks BA; Jiang J; Singh RA; Song W; Barry M; Huls MH; Slawin KM; Spencer DM
    Nat Med; 2005 Feb; 11(2):130-7. PubMed ID: 15665830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy.
    Dullaers M; Thielemans K
    J Gene Med; 2006 Jan; 8(1):3-17. PubMed ID: 16288497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway.
    Delcayre A; Shu H; Le Pecq JB
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):537-47. PubMed ID: 16001959
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimal control in a model of dendritic cell transfection cancer immunotherapy.
    Castiglione F; Piccoli B
    Bull Math Biol; 2006 Feb; 68(2):255-74. PubMed ID: 16794930
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune monitoring of cancer patients undergoing experimental immunotherapy.
    Shankar G; Salgaller ML
    Curr Opin Mol Ther; 2000 Feb; 2(1):66-73. PubMed ID: 11249653
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
    Bhargava A; Mishra D; Banerjee S; Mishra PK
    Immunotherapy; 2012 Jul; 4(7):703-18. PubMed ID: 22853757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent developments in therapeutic cancer vaccines.
    Morse MA; Chui S; Hobeika A; Lyerly HK; Clay T
    Nat Clin Pract Oncol; 2005 Feb; 2(2):108-13. PubMed ID: 16264883
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model.
    Yoneyama S; Okaji Y; Tsuno NH; Kawai K; Yamashita H; Tsuchiya T; Yamada J; Sunami E; Osada T; Kitayama J; Takahashi K; Nagawa H
    Eur J Surg Oncol; 2007 Dec; 33(10):1191-8. PubMed ID: 17314028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dendritic cells as natural adjuvants and modulators of immune response in cancer immunotherapy.
    Alli RS; Khar A
    Indian J Biochem Biophys; 2002 Dec; 39(6):363-7. PubMed ID: 22905392
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.